Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...

Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.

The investigational oral therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor, in a single tablet ...

Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term.

New HIV infections among gay and bisexual men in the United States have fallen over the past few years, in part due to earlier and more widespread use of effective antiretroviral therapy, according to ...

The Gauteng Department of Health has strengthened its STI prevention strategy through targeted screening, outreach, and HIV ...